Apimeds Pharmaceuticals US (APUS) Interest & Investment Income (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Interest & Investment Income of $35919.0 for Q4 2025, up 119630.0% on a YoY basis from N/an in Q4 2024, and down 36.34% quarter-over-quarter from $56426.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Interest & Investment Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Interest & Investment Income for 2 years, with the latest figure at $35919.0 in Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 119630.0% year-over-year to $35919.0; the trailing twelve-month figure through Dec 2025 stood at $107595.0 (up 3710.02% YoY), and the FY2025 full-year result was $107595.0, up 3710.02% from the prior year.
  • Interest & Investment Income for Q4 2025 stood at $35919.0, down from $56426.0 in the prior quarter.
  • The five-year high for Interest & Investment Income was $56426.0 in Q3 2025, with the low at $3.0 in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn -
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn -
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn 41.80 Mn
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn 3.45 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn 28.10 Mn
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn -
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn 8.54 Mn
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn 4.97 Mn
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn -
10 Apimeds Pharmaceuticals US 14.47 Mn 10.84 Mn - 35,919.00

Historic Data

Download Data
DateValue
Dec 31, 2025 35,919.00
Sep 30, 2025 56,426.00
Jun 30, 2025 15,247.00
Mar 31, 2025 3.00
Dec 31, 2024 30.00
Sep 30, 2024 116.00
Jun 30, 2024 517.00
Mar 31, 2024 2,161.00